Cardiovascular Outcomes With Tirzepatide Versus GLP ‐1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta‐Analysis
Pooled result · MACEResult — go to the resultHazard ratio 0.85 95% CI 0.70–1.04Authors' conclusion
Tirzepatide was not associated with a statistically significant reduction in MACEs.
Study context
- Population
- Adults with overweight or obesity; studies searched through 30 March 20268 studies (1 RCT, 7 observational)
- Participants
- 323,439 adults
- Comparison
- Tirzepatide vs GLP-1 RAs
- Outcome
- MACE
Methodological detailsadjusted hazard ratios when available, risk of bias assessed with RoB 2 and ROBINS-I
- Adjusted hazard ratios when available
- Risk of bias assessed with RoB 2 and ROBINS-I
Pooled result
As reported in the abstract
Hazard ratio
0.85
95% CI 0.70–1.04
Tirzepatidevs GLP-1 RAs
HR 0.85 (95% CI 0.70–1.04)
Further pooled results
All-cause mortality
- HR, tirzepatide vs GLP-1 RAs; directionally consistent with major adverse cardiovascular events (MACE)
- HR 0.90, 95% CI 0.79-1.02
CV mortality
- HR, tirzepatide vs GLP-1 RAs; directionally consistent with MACE
- HR 0.88, 95% CI 0.76-1.00
All-cause mortality, T2D subgroup
- Lower estimated risk in patients with T2D
- HR 0.85, 95% CI 0.76-0.94
- Exploratory subgroup analysis
HF, T2D subgroup
- Lower estimated risk in patients with T2D
- HR 0.75, 95% CI 0.58-0.97
- Exploratory subgroup analysis
Original publication
Cardiovascular Outcomes With Tirzepatide Versus GLP ‐1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 6 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →